Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:DMRA NASDAQ:HROW NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$4.00-4.8%$3.89$1.29▼$6.75$1.54B1.597.61 million shs4.56 million shsDMRADamora Therapeutics, Inc. Common Stock$24.87-4.1%$26.53$2.45▼$38.33$1.56B1.5238,866 shs142,526 shsHROWHarrow$40.50+0.7%$38.93$21.12▼$54.85$1.50B0.34494,569 shs442,215 shsRCKTRocket Pharmaceuticals$3.54-1.9%$4.11$2.19▼$7.77$393.93M0.522.15 million shs1.27 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley0.00%-4.61%+9.23%+6.98%+176.00%DMRADamora Therapeutics, Inc. Common Stock0.00%-0.55%+1.08%-0.98%+748.16%HROWHarrow0.00%-1.23%+15.83%-13.33%+58.34%RCKTRocket Pharmaceuticals0.00%+2.01%+0.28%+2.89%-55.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$4.00-4.8%$3.89$1.29▼$6.75$1.54B1.597.61 million shs4.56 million shsDMRADamora Therapeutics, Inc. Common Stock$24.87-4.1%$26.53$2.45▼$38.33$1.56B1.5238,866 shs142,526 shsHROWHarrow$40.50+0.7%$38.93$21.12▼$54.85$1.50B0.34494,569 shs442,215 shsRCKTRocket Pharmaceuticals$3.54-1.9%$4.11$2.19▼$7.77$393.93M0.522.15 million shs1.27 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley0.00%-4.61%+9.23%+6.98%+176.00%DMRADamora Therapeutics, Inc. Common Stock0.00%-0.55%+1.08%-0.98%+748.16%HROWHarrow0.00%-1.23%+15.83%-13.33%+58.34%RCKTRocket Pharmaceuticals0.00%+2.01%+0.28%+2.89%-55.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Beckley 3.00Buy$14.63265.63% UpsideDMRADamora Therapeutics, Inc. Common Stock 2.88Moderate Buy$43.4074.51% UpsideHROWHarrow 2.64Moderate Buy$69.8672.49% UpsideRCKTRocket Pharmaceuticals 2.39Hold$13.86291.44% UpsideCurrent Analyst Ratings BreakdownLatest RCKT, DMRA, HROW, and ATAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026DMRADamora Therapeutics, Inc. Common Stock Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$40.004/23/2026DMRADamora Therapeutics, Inc. Common Stock Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy4/22/2026HROWHarrow Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026ATAIAtai Beckley Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.004/17/2026ATAIAtai Beckley GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $16.004/17/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.004/7/2026HROWHarrow B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$74.00 ➝ $65.004/3/2026HROWHarrow Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/30/2026RCKTRocket Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.003/27/2026ATAIAtai Beckley Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Beckley$4.09M358.85N/AN/A$0.69 per share5.80DMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/A($110.11) per shareN/AHROWHarrow$272.30M5.54$0.87 per share46.51$1.41 per share28.72RCKTRocket PharmaceuticalsN/AN/AN/AN/A$2.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Beckley-$660.05M-$2.30N/AN/AN/A-16,142.01%-87.51%-63.88%5/13/2026 (Estimated)DMRADamora Therapeutics, Inc. Common Stock-$209.84M-$12.10N/AN/AN/AN/A-147.05%-279.49%5/5/2026 (Estimated)HROWHarrow-$5.14M-$0.17N/A16.40N/A-1.89%36.51%5.06%5/11/2026 (Estimated)RCKTRocket Pharmaceuticals-$223.12M-$2.01N/AN/AN/AN/A-64.74%-55.24%5/14/2026 (Estimated)Latest RCKT, DMRA, HROW, and ATAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026RCKTRocket Pharmaceuticals-$0.41N/AN/AN/A$4.47 millionN/A5/13/2026Q1 2026ATAIAtai Beckley-$0.11N/AN/AN/A$0.13 millionN/A5/11/2026Q1 2026HROWHarrow-$0.3538N/AN/AN/A$52.43 millionN/A5/5/2026Q1 2026DMRADamora Therapeutics, Inc. Common Stock-$0.3878N/AN/AN/AN/AN/A3/7/2026Q4 2025ATAIAtai Beckley-$0.12-$0.05+$0.07-$1.73$1.50 million$1.07 million2/26/2026Q4 2025RCKTRocket Pharmaceuticals-$0.42-$0.38+$0.04-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai BeckleyN/AN/AN/AN/AN/ADMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Beckley0.027.907.90DMRADamora Therapeutics, Inc. Common StockN/A12.9812.98HROWHarrow4.672.202.06RCKTRocket Pharmaceuticals0.076.386.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Beckley28.41%DMRADamora Therapeutics, Inc. Common Stock14.20%HROWHarrow72.76%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipATAIAtai Beckley26.80%DMRADamora Therapeutics, Inc. Common Stock10.46%HROWHarrow12.80%RCKTRocket Pharmaceuticals21.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Beckley80366.92 million268.58 millionOptionableDMRADamora Therapeutics, Inc. Common Stock4060.30 million54.00 millionNo DataHROWHarrow18037.27 million32.50 millionOptionableRCKTRocket Pharmaceuticals240109.12 million85.88 millionOptionableRCKT, DMRA, HROW, and ATAI HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI)April 29, 2026 | theglobeandmail.comRocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherApril 28, 2026 | joplinglobe.comJLifesci Capital Has Pessimistic Outlook of RCKT Q1 EarningsApril 21, 2026 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by BrokeragesApril 18, 2026 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)April 16, 2026 | theglobeandmail.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Short Interest UpdateApril 16, 2026 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving Average - Here's What HappenedApril 9, 2026 | marketbeat.comRCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseMarch 30, 2026 | zacks.comWhy Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADIMarch 29, 2026 | insidermonkey.comRocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 TranscriptMarch 27, 2026 | seekingalpha.comRocket Pharmaceuticals secures FDA approval for gene therapy KRESLADIMarch 27, 2026 | proactiveinvestors.caPRocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)March 27, 2026 | joplinglobe.comJRocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future ProductsMarch 27, 2026 | biospace.comBRocket Pharmaceuticals (RCKT) Stock Surges After FDA Approves Groundbreaking Gene TherapyMarch 27, 2026 | blockonomi.comRocket Pharma shares climb as FDA approves first therapy for deadly childhood disorderMarch 27, 2026 | reuters.comRocket Pharmaceuticals Launches New $100M At-The-Market ProgramMarch 10, 2026 | tipranks.comRocket Pharmaceuticals, Inc. (RCKT) Presents at Leerink Global Healthcare Conference 2026 TranscriptMarch 10, 2026 | seekingalpha.comWhy Rocket Pharmaceuticals, Inc.’s (RCKT) Stock Is Down 5.28%March 9, 2026 | aaii.comACanaccord Genuity Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)March 9, 2026 | theglobeandmail.comRocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference TranscriptMarch 6, 2026 | seekingalpha.comRCKT's Q4 Loss Narrower Than Estimated, Pipeline in FocusFebruary 27, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCKT, DMRA, HROW, and ATAI Company DescriptionsAtai Beckley NASDAQ:ATAI$4.00 -0.20 (-4.76%) Closing price 04:00 PM EasternExtended Trading$4.03 +0.03 (+0.75%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA$24.87 -1.06 (-4.09%) As of 04:00 PM EasternGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Harrow NASDAQ:HROW$40.50 +0.30 (+0.75%) Closing price 04:00 PM EasternExtended Trading$40.49 -0.01 (-0.02%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Rocket Pharmaceuticals NASDAQ:RCKT$3.54 -0.07 (-1.94%) Closing price 04:00 PM EasternExtended Trading$3.55 +0.01 (+0.28%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
